Rotator Cuff Pain After Menopause: What the Tendon Receptor Research Shows

What is rotator cuff disease, and why does it climb after menopause?

The rotator cuff is a group of four tendons that wrap the shoulder joint. They do the quiet work of keeping the arm bone centered in its socket while the big outer muscles do the lifting. The supraspinatus, the tendon that runs across the top of the shoulder, tears and frays more than any of the other three.

The condition is not a single event. It runs on a spectrum, from tendinopathy, where the tendon is irritated and thickened but intact, through partial tears, to full-thickness tears where the tendon has pulled away from the bone.

A recent concise review of tendon injury in physically active postmenopausal women put it plainly. This population carries a disproportionate burden of tendon and ligament injury, and rotator cuff disease sits near the top of the list. Clinical observation has long noted that it affects primarily women and occurs mainly in the postmenopausal period, well before the degenerative changes of old age would explain it on their own.

Why timing matters more than age here

Four patterns point at the menopausal transition itself, not just the passage of years.

• Rotator cuff disease becomes common earlier in women than the general wear-and-tear story would predict, clustering around menopause rather than climbing steadily with age alone.
• A 2026 national cohort study found hormone replacement therapy was associated with meaningfully lower odds of a tendon injury requiring surgical repair in perimenopausal women.
• The tissue itself changes composition at menopause. Tendons lose type I collagen content, the structural protein that gives them their tensile strength, independent of how much a woman has used her shoulder.
• Men develop rotator cuff tears too, but the acceleration tied specifically to a hormonal transition is a pattern seen in women.

None of this means every aching shoulder after 50 is hormonal. Overhead work, repetitive lifting, and simple accumulated use all contribute, in women and men alike. The research below addresses the piece of the picture that use alone does not explain.

What did the 2021 tendon biopsy study actually find?

Umile Giuseppe Longo and colleagues, publishing in BMC Musculoskeletal Disorders in 2021, collected supraspinatus tendon tissue intraoperatively from 24 patients undergoing rotator cuff surgery. Fifteen were postmenopausal women, nine were men. Every sample was stained and scored for estrogen receptor-alpha, estrogen receptor-beta, and progesterone receptor, then graded against the Bonar score, a standard measure of how degenerated tendon tissue looks under a microscope.

Here is the result that matters most. In the women's tendon samples, estrogen receptor-beta and progesterone receptor expression were both significantly higher than in the men's samples (p=0.048 and p=0.004). Only in the women did estrogen receptor-beta expression positively correlate with how degenerated the tendon looked.

Put plainly, the women's tendons were not just carrying more of these receptors. The amount of receptor tracked with the amount of damage.

The authors offered an explanation. Estrogen receptor-alpha is understood to mediate TGF-beta signaling and collagen synthesis in connective tissue, while estrogen receptor-beta is tied to cell apoptosis, programmed cell death that, when it runs unchecked, is associated with the tendon breakdown seen in cuff disease. In a 15-woman biopsy study, that reads as tissue trying to respond to a hormonal environment that has already shifted.

What this study does and does not prove

• Twenty-four patients is a real but small sample, and all of them already had tendon disease severe enough to need surgery. This describes damaged tissue, not a healthy comparison group.
• A correlation between receptor level and damage score is not proof the receptor caused the damage. It could just as easily mark tissue that is actively trying, and failing, to repair itself.
• The study did not measure these women's actual circulating estrogen levels, only the receptors inside the tendon itself.
• It is one study. A 2025 review of estrogen and progesterone's role in tendon matrix remodeling frames this as an active, still-developing area of research, not a settled mechanism.

How does losing estrogen change the tendon itself?

The clearest human evidence on what estrogen does inside tendon tissue comes from a different study, and it measured something more direct than receptor counts.

Mette Hansen and colleagues, publishing in the Journal of Applied Physiology in 2009, compared 10 postmenopausal women using oral estrogen therapy against 10 who were not. They used a stable-isotope tracer to directly measure how fast each woman's patellar tendon was building new collagen.

Tendon collagen synthesis was markedly higher in the estrogen users, reaching strong statistical significance (p<0.001). The authors concluded their data indicate a pivotal role for estradiol in maintaining homeostasis of female connective tissue.

That finding comes with real limits the study itself reported. The tendon's actual size and fibril density did not differ between the two groups. A separate marker of new collagen production, the propeptide marker, also did not differ. And the exercise-driven boost in collagen synthesis that normally follows a workout was negatively correlated with blood estradiol level, the opposite of what a simple more-estrogen-is-better story would predict.

So the honest version is narrow. Women taking estrogen were building resting-state tendon collagen at a markedly faster rate. It is not evidence that estrogen made their tendons bigger, stronger, or more resistant to injury, and this article makes no such claim.

Two threads, one tissue

Neither study tested a supplement of any kind. Both point at the same underlying tissue process. Estrogen decline and collagen production in tendon are connected, measured two different ways, in two different groups of postmenopausal women.

What does shilajit's own collagen research show?

No trial has tested shilajit, or any Optimum product, against rotator cuff disease, tendon tears, or shoulder pain of any kind. That comes first, before anything else here.

What exists is a human trial on the same structural protein these tendons are short on. Tyler Neltner and colleagues ran an 8-week randomized trial in 35 healthy men. They measured a direct blood marker of new type I collagen production, Pro-C1α1, at two shilajit doses against placebo.

The marker rose 94% at the 500 mg dose and 165% at the 1000 mg dose, climbing from a baseline around 42.7 ng/mL to 113.1 ng/mL at the higher dose. A marker of collagen breakdown, hydroxyproline, fell 29% at the lower dose over the same period.

That is the same collagen, type I, that makes up the bulk of tendon tissue, rising in the same direction the Hansen study found missing when estrogen falls. The two findings were never meant to be stacked into one. The Neltner trial ran in 35 men, not postmenopausal women, and it measured a circulating blood marker, not tendon tissue directly. It is evidence shilajit activates the collagen-building process this tissue depends on. It is not evidence it rebuilds a torn rotator cuff.

A separate line of shilajit research touches the other half of this picture. Fulvic acid, shilajit's primary active fraction, was shown in a 2015 laboratory study to block COX-2 expression and prostaglandin E2 secretion in human monocytes, by shutting down the same NF-kB inflammatory switch that ibuprofen and prescription anti-inflammatories target. Tendinopathy carries a real inflammatory component alongside the mechanical wear, and this is the inflammation side of the research, kept separate from the collagen side rather than blended into one claim.

Across every human clinical study ever conducted on shilajit, zero serious adverse events have been reported.

What is fair to say, and what is not

• Fair: shilajit's fulvic acid activates the gene pathway that builds type I collagen, measured directly in a human trial.
• Fair: a separate human study found collagen synthesis in postmenopausal tendon tissue runs faster when estrogen is present.
• Not fair: that shilajit has been shown to repair, strengthen, or prevent rotator cuff tears. No study has tested that.
• Not fair: that the Neltner trial's results in men transfer directly to postmenopausal women's tendons. The mechanism is the same protein. The population is not.

What actually helps a rotator cuff that already hurts?

The research with the strongest direct evidence, for an already-painful shoulder, is rehabilitation, not any supplement.

• Supervised rotator cuff and scapular strengthening exercise has the deepest evidence base for reducing pain and improving function in tendinopathy, and it works whether or not a tear is present.
• A 2026 study found postmenopausal women going into rotator cuff surgery while already on hormone replacement therapy had measurably better outcomes afterward than those who were not.
• Modifying overhead activity during a flare, without stopping shoulder movement entirely, keeps the tendon loaded enough to adapt without provoking it further.
• Sleeping positions that keep the arm supported, rather than pinned underneath the body, reduce the night pain many women report as the first and most disruptive symptom.
• A shoulder that cannot be lifted at all after a specific injury, or pain that is getting worse rather than better after several weeks of rest, is a signal to be examined rather than wait it out.

See Optimum Shilajit

We are family owned, out of Florida, and every box carries a 90 day money-back guarantee. See Optimum Shilajit

See See Optimum Shilajit